• Ann. Oncol. · Aug 2021

    A Multigenomic Liquid Biopsy Biomarker for Neuroendocrine Tumor Disease outperforms CgA and has Surgical and Clinical Utility.

    • I M Modlin, M Kidd, M Falconi, P L Filosso, A Frilling, A Malczewska, C Toumpanakis, G Valk, K Pacak, L Bodei, and K Oberg.
    • Yale University School of Medicine, New Haven, CT, USA.
    • Ann. Oncol. 2021 Aug 11.

    BackgroundBiomarkers are key tools in cancer management. In neuroendocrine tumors (NETs), Chromogranin A (CgA) was considered acceptable as a biomarker. We assessed the clinical efficacy of a multigenomic blood biomarker (NETest) to CgA over a 5-year period.MethodsAn observational, prospective, cross-sectional, multicenter, multinational, comparative cohort assessment. Cohort #1: NETest evaluation in NETs (1,684) and cancers, benign diseases, controls (731). Cohort #2: (n=1,270): matched analysis of NETest/CgA in a sub-cohort of NETs (n=922) vs. other diseases and controls (n=348). Disease status was assessed by RECIST. NETest measurement: qPCR (ULN: 20), CgA (EuroDiagnostica, ULN: 108ng/mL).StatisticsMann-Whitney U-test, AUROC, Chi2 and McNemar's test.ResultsCohort #1: NETest diagnostic accuracy was 91% (p<0.0001) and identified pheochromocytomas (98%), small intestine (94%), pancreas (91%), lung (88%), gastric (80%) and appendix (79%). NETest reflected grading: G1: 40±1, G2 (50±1) and G3 (52±1). Loco-regional disease levels were lower (38±1) than metastatic (52±1, p<0.0001). NETest accurately stratified RECIST-assessed disease extent: no disease (21±1), stable (43±2), progressive (62±2) (p<0.0001). NETest concordance with imaging (CT/MRI/68Ga-SSA-PET) 91%. Pre-surgery, all NETs (n=153) were positive (100%). After palliative R1/R2 surgery (n=51) all (100%) remained elevated. After curative R0-surgery (n=102), NETest levels were normal in 81(70%) with no recurrence at 2 years. In the 31 (30%) with elevated levels, 25 (81%) recurred within 2 years. Cohort #2: NETest diagnostic accuracy was 87% and CgA 54% (p<0.0001). NETest was more accurate than CgA for grading (Chi2=7.7, OR=18.5) and metastatic identification (Chi2=180, OR=8.4). NETest identified progressive disease (95%) vs CgA (57%, p<0.0001). Imaging concordance for NETest was 91% vs. CgA (46%) (p<0.0001). Recurrence prediction after surgery was NETest-positive in >94% vs. CgA 11%.ConclusionNETest accurately diagnoses NETs and is an effective surrogate marker for imaging, grade, metastases and disease status compared to CgA. A multigenomic liquid biopsy is an accurate biomarker of NET disease.Copyright © 2021. Published by Elsevier Ltd.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…